AR083018A1 - Uso de un compuesto de [3-(1-(1h-imidazol-4-il)etil)-2-metilfenil]metanol para preparar un medicamento util para la reduccion de la presion intraocular, articulo de fabricacion y composicion farmaceutica que lo comprenden - Google Patents

Uso de un compuesto de [3-(1-(1h-imidazol-4-il)etil)-2-metilfenil]metanol para preparar un medicamento util para la reduccion de la presion intraocular, articulo de fabricacion y composicion farmaceutica que lo comprenden

Info

Publication number
AR083018A1
AR083018A1 ARP110103390A ARP110103390A AR083018A1 AR 083018 A1 AR083018 A1 AR 083018A1 AR P110103390 A ARP110103390 A AR P110103390A AR P110103390 A ARP110103390 A AR P110103390A AR 083018 A1 AR083018 A1 AR 083018A1
Authority
AR
Argentina
Prior art keywords
methyl
imidazol
ethyl
amino
butyric acid
Prior art date
Application number
ARP110103390A
Other languages
English (en)
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44675870&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR083018(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of AR083018A1 publication Critical patent/AR083018A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Uso de un compuesto de [3-(1-(1H-imidazol-4-il)etil)-2-metilfenil]metanol que tiene la fórmula (1), (2) ó (3), sus enantiómeros individuales, sus diastereoisómeros, sus hidratos, sus solvatos, sus formas cristalinas, sus isómeros individuales, sus tautómeros individuales o una sal farmacéuticamente. aceptable de la misma, donde R1 es H o alquilo C1-3; R2 es H o alquilo C1-3; R3 es H, alquilo C1-10, heterociclo o arilo; y R es alquilo C1-10, heterociclo o arilo; para preparar un medicamento útil para la reducción de la presión intraocular. Artículo de fabricación y composición farmacéutica que comprenden dicho compuesto.Reivindicación 6: El uso de acuerdo con la reivindicación 2, caracterizado porque el compuesto está seleccionado de: éster 3-[(S)-1-(1H-imidazol-4-il)-etil]-2-metil-bencílico del ácido iso-butírico; éster 3-[(S)-1-(1H-imidazol-4-il)-etil]-2-metil-bencílico del ácido 2,2-dimetil-propiónico; éster 3-[(S)-1-(1H-imidazol-4-il)-etil]-2-metil-bencílico del ácido acético; éster 3-[(S)-1-(1H-imidazol-4-il)-etil]-2-metil-bencílico de ácido benzoico; éster 3-[(S)-1-(1H-imidazol-4-il)-etil]-2-metil-bencílico del ácido 3-metil-butírico; éster 3-[(S)-1-(1H-imidazol-4-il)-etil]-2-metil-bencílico del ácido 3-fenil-propiónico; éster 3-[(S)-1-(1H-imidazol-4-il)-etil]-2-metil-bencílico del ácido 2-amino-3-metil-butírico; éster 3-[(S)-1-(1H-imidazol-4-il)-etil]-2-metil-bencílico del ácido 2-(2-amino-3-metil-butirilamino)-3-metil-butírico; éster 3-[(S)-1-(1H-imidazol-4-il)-etil]-2-metil-bencílico del ácido 2-(2-amino-acetilamino)-3-metil-butírico; y éster 3-[(S)-1-(1H-imidazol-4-il)-etil]-2-metil-bencílico del ácido 2-amino-3-fenil-propiónico.
ARP110103390A 2010-09-16 2011-09-16 Uso de un compuesto de [3-(1-(1h-imidazol-4-il)etil)-2-metilfenil]metanol para preparar un medicamento util para la reduccion de la presion intraocular, articulo de fabricacion y composicion farmaceutica que lo comprenden AR083018A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US38337010P 2010-09-16 2010-09-16

Publications (1)

Publication Number Publication Date
AR083018A1 true AR083018A1 (es) 2013-01-23

Family

ID=44675870

Family Applications (4)

Application Number Title Priority Date Filing Date
ARP110103391A AR083019A1 (es) 2010-09-16 2011-09-16 Uso de un compuesto de [3-(1-(1h-imidazol-4-il)etil)-2-metilfenil]metanol para preparar un medicamento util para tratar enfermedades de la retina, articulo de fabricacion y composicion farmaceutica que lo comprenden
ARP110103389A AR083017A1 (es) 2010-09-16 2011-09-16 Prodrogas de ester de [3-(1-(1h-imidazol-4-il)etil)-2-metilfenil]metanol
ARP110103390A AR083018A1 (es) 2010-09-16 2011-09-16 Uso de un compuesto de [3-(1-(1h-imidazol-4-il)etil)-2-metilfenil]metanol para preparar un medicamento util para la reduccion de la presion intraocular, articulo de fabricacion y composicion farmaceutica que lo comprenden
ARP110103392A AR083020A1 (es) 2010-09-16 2011-09-16 Uso de un compuesto de [3-(1-(1h-imidazol-4-il)etil)-2-metilfenil]metanol para preparar un medicamento util para tratar enfermedades y afecciones de la piel, articulo de fabricacion y composicion farmaceutica que lo comprenden

Family Applications Before (2)

Application Number Title Priority Date Filing Date
ARP110103391A AR083019A1 (es) 2010-09-16 2011-09-16 Uso de un compuesto de [3-(1-(1h-imidazol-4-il)etil)-2-metilfenil]metanol para preparar un medicamento util para tratar enfermedades de la retina, articulo de fabricacion y composicion farmaceutica que lo comprenden
ARP110103389A AR083017A1 (es) 2010-09-16 2011-09-16 Prodrogas de ester de [3-(1-(1h-imidazol-4-il)etil)-2-metilfenil]metanol

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP110103392A AR083020A1 (es) 2010-09-16 2011-09-16 Uso de un compuesto de [3-(1-(1h-imidazol-4-il)etil)-2-metilfenil]metanol para preparar un medicamento util para tratar enfermedades y afecciones de la piel, articulo de fabricacion y composicion farmaceutica que lo comprenden

Country Status (29)

Country Link
US (9) US8653123B2 (es)
EP (13) EP2616066B1 (es)
JP (4) JP6045495B2 (es)
KR (7) KR101840501B1 (es)
CN (5) CN103221045A (es)
AR (4) AR083019A1 (es)
AU (4) AU2011301847B2 (es)
BR (4) BR112013006320B1 (es)
CA (8) CA3116249A1 (es)
CL (4) CL2013000736A1 (es)
CY (3) CY1121024T1 (es)
DK (9) DK3050563T3 (es)
ES (10) ES2607084T3 (es)
HK (5) HK1185540A1 (es)
HU (5) HUE047476T2 (es)
IL (4) IL225282A0 (es)
MX (4) MX2013003004A (es)
MY (4) MY161607A (es)
NZ (1) NZ608751A (es)
PL (7) PL3338777T3 (es)
PT (7) PT3050564T (es)
RU (4) RU2013116405A (es)
SG (4) SG188573A1 (es)
SI (5) SI3348264T1 (es)
TR (1) TR201909249T4 (es)
TW (4) TWI591058B (es)
UA (1) UA112973C2 (es)
WO (4) WO2012037484A1 (es)
ZA (4) ZA201302194B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2395999B1 (en) 2009-02-13 2017-09-13 Allergan, Inc. Pharmaceutical compositions comprising (3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl)methanol
EP3659604A1 (en) 2010-01-11 2020-06-03 Nalpropion Pharmaceuticals, Inc. Methods of providing weight loss therapy in patients with major depression
US8653123B2 (en) * 2010-09-16 2014-02-18 Allergan, Inc. Ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for treating retinal diseases
CA2842866A1 (en) * 2011-07-22 2013-01-31 Allergan, Inc. Alpha-2 adrenergic modulators for treating visual disorders mediated by central visual projections from the eye
US9095576B2 (en) 2011-11-21 2015-08-04 Allergan, Inc. Pharmaceutical compositions comprising 4-[1-(2,3-dimethylphenyl)ethyl]-3H-imidazole derivatives for treating retinal diseases
USD794650S1 (en) 2014-11-28 2017-08-15 Samsung Electronics Co., Ltd. Display screen or portion thereof with a graphical user interface
CN108310442B (zh) * 2017-01-17 2021-08-27 台北科技大学 眼科用组合物
KR102050506B1 (ko) 2017-06-20 2019-11-29 한국식품연구원 망막 질환 예방, 개선, 완화 또는 치료용 조성물
CN108872431B (zh) * 2018-07-09 2021-03-23 成都倍特药业股份有限公司 一种检测4-(1-(2,5-二甲基苯基)乙基)-1h-咪唑或/和其盐酸盐的方法
US20240287093A1 (en) * 2018-08-24 2024-08-29 Adlai Nortye Biopharma Co., Ltd. High activity sting protein agonist
MX2023012132A (es) * 2021-04-16 2023-10-25 Ads Therapeutics Llc Cofarmacos agonistas alfa-2 adrenergicos conjugados con farmacos agonistas muscarinicos.
WO2024167962A1 (en) * 2023-02-08 2024-08-15 Whitecap Biosciences Llc Alpha-2-adrenergic agonists for improving vision

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0642332B1 (en) 1992-05-13 1997-01-15 Sandoz Ltd. Ophthalmic compositions containing a cyclosporin
US5459133A (en) * 1992-06-05 1995-10-17 Telor Ophthalmic Pharmaceuticals, Inc. Methods and products for treating presbyopia
EP0729459B1 (en) 1993-11-15 2003-03-12 Schering Corporation Phenyl-alkyl imidazoles as h3-receptor antagonists
US5474979A (en) 1994-05-17 1995-12-12 Allergan, Inc. Nonirritating emulsions for sensitive tissue
EP0957073A1 (en) * 1998-05-12 1999-11-17 Schwarz Pharma Ag Novel derivatives of 3,3-diphenylpropylamines
US20040214829A1 (en) * 2000-07-14 2004-10-28 Allergan, Inc. Compositions containing alpha-2-adrenergic agonist components
US20020198209A1 (en) 2001-05-03 2002-12-26 Allergan Sales Inc. Compositions having enhanced pharmacokinetic characteristics
US7439241B2 (en) * 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
MXPA05012679A (es) * 2003-05-27 2006-02-08 Sod Conseils Rech Applic Nuevos derivados de imidazoles, su preparacion y su uso como medicamento.
JP2007528020A (ja) * 2003-07-14 2007-10-04 コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ 投影装置
KR20060126448A (ko) 2003-09-12 2006-12-07 알러간, 인코포레이티드 통증 및 다른 알파 2 아드레날린 매개 증상을 치료하기위한 방법 및 조성물
US20050059583A1 (en) 2003-09-15 2005-03-17 Allergan, Inc. Methods of providing therapeutic effects using cyclosporin components
US20050244463A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular vasculopathies
JP4955543B2 (ja) * 2004-05-25 2012-06-20 サンズローザ ファーマシューティカル ディヴェロップメント インコーポレイテッド 炎症性皮膚疾患を治療又は予防するための化合物、製剤及び方法
US20050277584A1 (en) 2004-06-09 2005-12-15 Allergan, Inc. Pharmaceutical compositions comprising cyclosporins
BRPI0516083A (pt) * 2004-09-24 2008-08-19 Allergan Sales Inc 4-(fenilmetil e 4-fenilmetil substituìdo)-imidazol-2-tionas que atuam como agonistas alfa2 adrenérgicos
US7931909B2 (en) 2005-05-10 2011-04-26 Allergan, Inc. Ocular therapy using alpha-2 adrenergic receptor compounds having enhanced anterior clearance rates
US20070015691A1 (en) 2005-07-13 2007-01-18 Allergan, Inc. Cyclosporin compositions
US7297679B2 (en) 2005-07-13 2007-11-20 Allergan, Inc. Cyclosporin compositions
US20070082070A1 (en) * 2005-10-11 2007-04-12 Stookey Evangeline L Treating skin disorders
US7902247B2 (en) 2008-01-09 2011-03-08 Allergan, Inc. Substituted-aryl-2-phenylethyl-1H-imidazole compounds as subtype selective modulators of alpha 2B and/or alpha 2C adrenergic receptors
US20110306635A1 (en) 2009-02-06 2011-12-15 Allergan ,Inc. Pyridine compounds as subtype selective modulators of alpha2b and /or alpha 2c adrenergic receptors
EP2395999B1 (en) * 2009-02-13 2017-09-13 Allergan, Inc. Pharmaceutical compositions comprising (3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl)methanol
US8394800B2 (en) * 2009-11-19 2013-03-12 Galderma Laboratories, L.P. Method for treating psoriasis
US8653123B2 (en) * 2010-09-16 2014-02-18 Allergan, Inc. Ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for treating retinal diseases

Also Published As

Publication number Publication date
ES2737230T3 (es) 2020-01-10
EP3050563B1 (en) 2018-05-09
AU2011301856A1 (en) 2013-05-02
CN103221045A (zh) 2013-07-24
BR112013006320A2 (pt) 2016-06-21
IL225281A0 (en) 2013-06-27
JP2013537237A (ja) 2013-09-30
US8492422B2 (en) 2013-07-23
US8653123B2 (en) 2014-02-18
DK3348264T3 (da) 2020-03-23
AR083020A1 (es) 2013-01-23
EP3659600A1 (en) 2020-06-03
SI3050563T1 (sl) 2018-10-30
TW201305117A (zh) 2013-02-01
DK2616069T3 (en) 2016-12-19
US20120149746A1 (en) 2012-06-14
WO2012037453A1 (en) 2012-03-22
US20120136036A1 (en) 2012-05-31
MX2013003009A (es) 2013-06-28
KR20130105658A (ko) 2013-09-25
RU2013116763A (ru) 2014-10-27
EP3698789A1 (en) 2020-08-26
CA3122745A1 (en) 2012-03-22
CN103200941A (zh) 2013-07-10
ES2593612T3 (es) 2016-12-12
SG188573A1 (en) 2013-04-30
EP3348264A1 (en) 2018-07-18
KR102104760B1 (ko) 2020-04-27
MY191369A (en) 2022-06-20
DK3050563T3 (en) 2018-08-13
CN103200941B (zh) 2015-12-16
BR112013006352A2 (pt) 2016-06-28
EP3348264B1 (en) 2020-01-01
EP2616069A1 (en) 2013-07-24
BR112013006320B1 (pt) 2022-08-30
CN103200942A (zh) 2013-07-10
PT3053576T (pt) 2018-10-08
ES2760920T3 (es) 2020-05-18
US8492557B2 (en) 2013-07-23
HK1257416A1 (zh) 2019-10-18
ES2607084T3 (es) 2017-03-29
CA2811559A1 (en) 2012-03-22
MY168763A (en) 2018-12-04
CA2812191C (en) 2021-04-13
SI3338777T1 (sl) 2020-08-31
IL225278A0 (en) 2013-06-27
ES2687420T3 (es) 2018-10-25
TW201240661A (en) 2012-10-16
DK3053576T3 (en) 2018-08-20
CA2812191A1 (en) 2012-03-22
KR20190022895A (ko) 2019-03-06
MY161607A (en) 2017-04-28
DK3338777T3 (da) 2020-04-20
RU2013116403A (ru) 2014-10-27
WO2012037499A1 (en) 2012-03-22
SG188570A1 (en) 2013-04-30
TR201909249T4 (tr) 2019-07-22
CN103209694A (zh) 2013-07-17
EP3636263B1 (en) 2021-11-03
PT3050564T (pt) 2019-12-11
CL2013000735A1 (es) 2013-11-29
MX2013003004A (es) 2013-06-28
PL2616068T3 (pl) 2016-11-30
KR101840501B1 (ko) 2018-05-04
RU2612351C2 (ru) 2017-03-07
EP3050564A1 (en) 2016-08-03
CN105412092B (zh) 2020-11-17
MY173846A (en) 2020-02-24
EP2616068B1 (en) 2016-07-13
HK1185540A1 (zh) 2014-02-21
PL3050563T3 (pl) 2018-12-31
IL225282A0 (en) 2013-06-27
EP3050564B1 (en) 2019-09-04
CA3116249A1 (en) 2012-03-22
EP2616066B1 (en) 2016-07-13
CA2812195A1 (en) 2012-03-22
TWI591058B (zh) 2017-07-11
PT2616068T (pt) 2016-09-13
PT3348264T (pt) 2020-04-02
US20150148394A1 (en) 2015-05-28
EP2616068A1 (en) 2013-07-24
JP2013540749A (ja) 2013-11-07
CY1122809T1 (el) 2021-05-05
WO2012037484A1 (en) 2012-03-22
EP2616067B1 (en) 2016-05-18
KR101840500B1 (ko) 2018-03-20
EP2616069B1 (en) 2016-11-16
KR20200044147A (ko) 2020-04-28
ES2613509T3 (es) 2017-05-24
IL225278A (en) 2015-11-30
PT3338777T (pt) 2020-05-06
NZ608751A (en) 2015-04-24
ZA201302193B (en) 2013-11-27
DK2616068T3 (en) 2016-08-29
CA3077732A1 (en) 2012-03-22
JP2013541527A (ja) 2013-11-14
ES2781681T3 (es) 2020-09-04
DK3050564T3 (da) 2019-11-25
CA3079450A1 (en) 2012-03-22
TW201240662A (en) 2012-10-16
SI3348264T1 (sl) 2020-07-31
US8501796B2 (en) 2013-08-06
KR20140005154A (ko) 2014-01-14
ZA201302291B (en) 2013-11-27
JP6073229B2 (ja) 2017-02-01
CL2013000736A1 (es) 2013-07-12
MX2013003008A (es) 2013-06-28
AU2011301901A1 (en) 2013-05-02
ZA201302194B (en) 2013-11-27
US20120122945A1 (en) 2012-05-17
PL3050564T3 (pl) 2020-06-01
AU2011301847B2 (en) 2016-02-11
KR101952457B1 (ko) 2019-02-26
BR112013006355A2 (pt) 2016-06-28
SG188572A1 (en) 2013-04-30
KR102354097B1 (ko) 2022-01-20
RU2013116405A (ru) 2014-10-27
CL2013000734A1 (es) 2013-11-08
DK3078376T3 (da) 2019-06-24
US20130296394A1 (en) 2013-11-07
RU2013116541A (ru) 2014-10-27
HUE049573T2 (hu) 2020-10-28
JP6045495B2 (ja) 2016-12-14
SG188571A1 (en) 2013-04-30
WO2012037490A1 (en) 2012-03-22
EP2616066A1 (en) 2013-07-24
ES2788051T3 (es) 2020-10-20
PL3338777T3 (pl) 2020-07-13
SI3050564T1 (sl) 2020-02-28
IL225280A0 (en) 2013-06-27
PT2616069T (pt) 2016-12-06
AR083019A1 (es) 2013-01-23
AU2011301932A1 (en) 2013-05-02
SI3053576T1 (sl) 2018-11-30
CY1121024T1 (el) 2019-12-11
HK1185541A1 (zh) 2014-02-21
EP3053576A1 (en) 2016-08-10
CL2013000733A1 (es) 2013-08-23
MX2013003002A (es) 2013-06-28
CA2812197A1 (en) 2012-03-22
HUE048725T2 (hu) 2020-09-28
HUE039090T2 (hu) 2018-12-28
EP3636263A1 (en) 2020-04-15
CN105412092A (zh) 2016-03-23
EP3050563A1 (en) 2016-08-03
ES2684055T3 (es) 2018-10-01
HUE038698T2 (hu) 2018-11-28
PL3053576T3 (pl) 2018-11-30
EP3338777A1 (en) 2018-06-27
US20160354346A1 (en) 2016-12-08
KR20140003407A (ko) 2014-01-09
ZA201302288B (en) 2013-11-27
AU2011301932C1 (en) 2016-09-01
CA2812197C (en) 2024-01-02
PL2616069T3 (pl) 2017-04-28
PT3050563T (pt) 2018-10-01
ES2904479T3 (es) 2022-04-05
US20130289088A1 (en) 2013-10-31
PL3348264T3 (pl) 2020-08-24
KR20200091507A (ko) 2020-07-30
HK1185539A1 (zh) 2014-02-21
EP3078376A1 (en) 2016-10-12
AR083017A1 (es) 2013-01-23
BR112013006362A2 (pt) 2016-06-28
TW201305116A (zh) 2013-02-01
KR102139905B1 (ko) 2020-07-31
UA112973C2 (uk) 2016-11-25
JP2013537236A (ja) 2013-09-30
KR20130114140A (ko) 2013-10-16
US8853251B2 (en) 2014-10-07
EP3338777B1 (en) 2020-02-05
US20140057958A1 (en) 2014-02-27
HK1185538A1 (zh) 2014-02-21
US20120142746A1 (en) 2012-06-07
AU2011301932B2 (en) 2016-02-25
DK3636263T3 (da) 2022-01-10
EP3078376B1 (en) 2019-03-27
AU2011301856C1 (en) 2016-09-08
EP3053576B1 (en) 2018-05-16
AU2011301901B2 (en) 2016-02-11
CY1122958T1 (el) 2021-10-29
HUE047476T2 (hu) 2020-04-28
AU2011301847A1 (en) 2013-05-02
EP2616067A1 (en) 2013-07-24

Similar Documents

Publication Publication Date Title
AR083018A1 (es) Uso de un compuesto de [3-(1-(1h-imidazol-4-il)etil)-2-metilfenil]metanol para preparar un medicamento util para la reduccion de la presion intraocular, articulo de fabricacion y composicion farmaceutica que lo comprenden
CY1124874T1 (el) Διεργασια για την παρασκευη [(5-(3-χλωροφαινυλ)-3-υδροξυπυριδινο-2-καρβονυλ)-αμινο]οξικου οξεος απο 5-((3-χλωροφαινυλ)-3-χλωρο-πυριδιν-2-υλ)-νιτριλιο, και διεργασια για την παρασκευη παραγωγων 5-((αλογονοφαινυλ)-3-αλογονο-πυριδιν-2-υλ)-νιτριλιου
AR112074A2 (es) Derivados de 2-carboxamida-cicloamino-urea como inhibidores de pi-3
AR068045A1 (es) Derivados de catecolamina y prodrogas de los mismos
AR050463A1 (es) Analagos de lonidamina y su uso en anticoncepcion masculina y en el tratamiento contra el cancer.
UY35401A (es) ?compuestos aromáticos sustituidos para el tratamiento de la fibrosis pulmonar, la fibrosis hepática, la fibrosis de la piel y la fibrosis cardíaca?.
NI200800227A (es) Acidos 1,3-dioxano carboxilicos
NZ590355A (en) Stat3 inhibitor containing quinolinecarboxamide derivative as active ingredient
CL2009000815A1 (es) Compuestos derivados de fenilhidroximetilpirrolidina, agonista del recptor adrenergico beta 3; composicion farmaceutica que los comprende; uso en el tratamiento de vejiga hiperactiva, incontinencia urinaria por impulso y urgencia urinaria.
AR070531A1 (es) Inhibidores de cinasa pim y metodos para su uso
CA2725933A1 (en) Drug combinations comprising a dgat inhibitor and a ppar-agonist
CL2011003276A1 (es) Compuesto amida del ácido {5-[4-{3,3-dimetll-azetidina-1-carbonil)-fenil]-[l,2,4]trlaz010[l,5-a]piridin-2-1i} clclopropanocarboxillco; inhibldor de jak1: composición farmacéutica que lo comprende: uso del compuesto en la profilaxis ylo tratamiento de afecciones inflamatorias, autolnmunltarias, proliferativas, entre otras.
ECSP099586A (es) Derivado de triazol
AR062394A1 (es) Uso de compuestos y derivados de 2,5-dihidroxibenceno para el tratamiento de la psoriasis
TW200745097A (en) 4-Phenyl-thiazole-5-carboxylic acids and 4-phenyl-thiazole-5-carboxylic acid amides as PLK1 inhibitors
WO2012161518A3 (ko) ＲＯＲα의 활성자로서의 신규한 ｔｈｉｏｕｒｅａ 유도체 및 이를 함유하는 약학적 조성물
CR20110669A (es) Ácido trans-4-[[(5s)-5-[[[3,5-bis(trifluorometil)fenil]metil] (2-metil-2h-tetrazol-5-il)amino]-2,3,4,5-tetrahidro-7,9-dimetil-1h-1-benzazepin-1-il]metil]-ciclohexancarboxílico
CO2022004978A2 (es) Inhibidor de irak y método de preparación para el mismo y uso del mismo
CO6361939A2 (es) 5- (2-{ [6- (2, 2-difluoro-2-feniletoxi) hexil] amino} -1-hidroxietil) -8-hidroxiquinolin-2 (ih)-ona para el tratamiento pulmonar
RU2012134065A (ru) Альфа-2 адренергический агонист, обладающий эффектом длительного снижения внутриглазного давления
PE20090445A1 (es) Inhibidores de produccion de beta amiloide
NZ590454A (en) Glucocorticoids attached to nitrate esters via an aromatic linker in position 21 and their use in ophthalmology
WO2010040862A3 (en) New activators for treating and/or preventing diseases or medical conditions which benefit from an increased transport of hyaluronan across a lipid bilayer
ATE455769T1 (de) Substituierte thiazole und ihre verwendung zur herstellung von arzneimitteln
AR083322A1 (es) Compuesto (3-{[{4-[4-amino-2-(etoximetil)-1h-imidazol[4,5-c]quinolin-1-il]butil}(n,n-dietilglicil)amino]metil}fenil)acetato de metilo

Legal Events

Date Code Title Description
FB Suspension of granting procedure